National Institute on Drug Abuse; Notice of Closed Meetings, 102918-102919 [2024-29831]
Download as PDF
<![CDATA[
102918
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel: Mechanism for TimeSensitive Research Opportunities in
Environmental Health Sciences (R21).
Date: January 15, 2025.
Time: 11:30 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of
Environmental Health Sciences, Keystone
Building, 530 Davis Drive, Durham, NC
27709.
Meeting Format: Virtual Meeting.
Contact Person: Murali Ganesan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training (DERT), National Institute of
Environmental Health Sciences, National
Institutes of Health, Keystone Building,
Room 3097, Research Triangle Park, NC
27713, Phone: 984–287–4674, Email:
murali.ganesan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: December 12, 2024.
Bruce A. George,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–29836 Filed 12–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSK9W7S144PROD with NOTICES
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
18:09 Dec 17, 2024
Jkt 265001
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; EarlyStage Dissemination and Implementation
Research in Communication Disorders.
Date: January 16, 2025.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Boulevard, Room 8351, Bethesda,
MD 20892, (301) 451–6339, kellya2@nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Inner Ear
Imaging RFA Review.
Date: January 30, 2025.
Time: 1:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Blvd., Rockville, MD 20852, 301–
402–3587, rayk@nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; NIDCD
Institutional Research Training Opportunities
Review.
Date: January 31, 2025.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Andrea B. Kelly, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Boulevard, Room 8351, Bethesda,
MD 20892, (301) 451–6339, kellya2@nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; NIDCD
Clinical Research Center Grant (P50) Review.
Date: February 6, 2025.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health, 6001
Executive Blvd., Rockville, MD 20852, 301–
402–3587, rayk@nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Disorders Special Emphasis Panel;
Chemosensory Fellowship Review Meeting.
Date: February 11, 2025.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Meeting Format: Virtual Meeting.
Contact Person: Sonia Elena Nanescu,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, NIDCD, NIH, 6001
Executive Blvd., Suite 8300, Bethesda, MD
20892, (301) 496–8683, sonia.nanescu@
nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Hearing
and Balance Fellowship Review.
Date: February 21, 2025.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: Hilton Garden Inn Seaworld
Orlando, FL.
Meeting Format: Virtual Meeting.
Contact Person: Martin Basch, Ph.D.,
Scientific Review Officer, NIH/NIDCD,
Scientific Review Branch, 6001 Executive
Blvd., Suite 8300, Bethesda, MD 20892, (301)
496–9693, martin.basch@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: December 12, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–29910 Filed 12–17–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Translating Research to Practice to
End the Overdose Crisis.
E:\FR\FM\18DEN1.SGM
18DEN1
khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices
Date: January 23–24, 2025.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
REI: Research at Minority Serving
Institutions on Neurocognitive Mechanisms
Underlying the Impact of Structural Racism
on the Substance Use Trajectory.
Date: February 3, 2025.
Time: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Shareen Amina Iqbal,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Digital Therapeutics for
Substance Use Disorders.
Date: February 5, 2025.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Shareen Amina Iqbal,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
shareen.iqbal@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: December 12, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–29831 Filed 12–17–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:09 Dec 17, 2024
Jkt 265001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
The National Institutes of Health Public
Access Policy
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The 2024 National Institutes
of Health (NIH) Public Access Policy
implements additional steps to
accelerate free public access to scholarly
publications resulting from the research
that NIH supports, building upon NIH’s
long history of providing public access
to research results.
FOR FURTHER INFORMATION CONTACT:
Hilary Leeds, J.D., Senior Policy Analyst
for Public Access, Office of Science
Policy, at (301) 496–9838 or
SciencePolicy@od.nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Background
Increasing access to publications
resulting from the National Institutes of
Health (NIH) funding offers many
benefits to the scientific community and
the public who funded the underlying
research. When patients, families, and
healthcare providers can access
published findings resulting from NIH
funding, they are able to better
understand and address the most
critical health concerns facing their
communities. It also allows researchers,
students, and members of the public in
all communities to have equitable
access to such content. This access can
accelerate future research, lead to
collaboration, and allow interested
readers and patients to follow the latest
advances more closely. Importantly,
these goals reflect NIH’s commitment to
the responsible stewardship of the
Nation’s investment in biomedical
research by improving transparency and
accessibility of taxpayer-funded
research, an essential component of
fostering trust in research. NIH is
issuing this updated Public Access
Policy to further advance these goals by
accelerating free public access to
research results.
NIH has a long history of providing
access to research products resulting
from its funded research. The NIH
Public Access Policy https://
sharing.nih.gov/public-access-policy/
public-access-policy-overview in effect
since 2008, requires that NIH-supported
researchers submit their final peerreviewed manuscripts to the National
Library of Medicine’s PubMed Central®
digital archive of full-text biomedical
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
102919
and life sciences journal literature upon
acceptance for publication, to be made
freely available to the public after an
allowable embargo period of not more
than 12 months after the official date of
publication. The 2008 Policy
implements Public Law 110–161
https://www.congress.gov/110/statute/
STATUTE-121/STATUTE-121Pg1844.pdf, which was made a
legislative mandate for FY 2009 and
beyond by Public Law 111–8 https://
www.govinfo.gov/content/pkg/PLAW111publ8/pdf/PLAW-111publ8.pdf. The
Policy has, to date, resulted in more
than 1.5 million articles reporting on
NIH-supported research being freely
available to the public in PubMed
Central.
On August 25, 2022, the White House
Office of Science and Technology Policy
(OSTP) released updated policy
guidance (2022 OSTP Memorandum
https://www.whitehouse.gov/wpcontent/uploads/2022/08/08-2022OSTP-Public-Access-Memo.pdf) to all
federal agencies with research and
development expenditures to further
promote equity, advance trust in
science, and continue to advance
American scientific leadership.
Following the 2022 OSTP
Memorandum, NIH released its Plan to
Enhance Public Access to the Results of
NIH-Supported Research https://
grants.nih.gov/grants/guide/notice-files/
NOT-OD-23-091.html in February 2023
(hereafter, the NIH Public Access Plan)
and its Draft Public Access Policy
https://www.federalregister.gov/
documents/2024/06/18/2024-13373/
request-for-information-on-the-nationalinstitutes-of-health-draft-public-accesspolicy in June 2024 (NIH Draft Public
Access Policy). The NIH Public Access
Plan and Draft Public Access Policy
provided a roadmap for how NIH
proposed to accelerate access to
scholarly publications, consistent with
the government-wide expectation to
remove the 12-month embargo period
before public availability. This 2024
NIH Public Access Policy is consistent
with the expectations of the 2022 OSTP
Memorandum regarding scholarly
publications and is informed by all
public feedback, including comments
submitted in response to the NIH Draft
Public Access Policy.
Overview of Public Comments
A total of 144 written public
comments https://osp.od.nih.gov/wpcontent/uploads/2024/10/CompiledPublic-Comments-on-RFI-on-the-NIHDraft-Public-Access-Policy-508C.pdf
were received in response to the NIH
Draft Public Access Policy. Written
comments were received from a variety
E:\FR\FM\18DEN1.SGM
18DEN1
]]>Agencies
[Federal Register Volume 89, Number 243 (Wednesday, December 18, 2024)]
[Notices]
[Pages 102918-102919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29831]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: Translating Research to Practice to
End the Overdose Crisis.
[[Page 102919]]
Date: January 23-24, 2025.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA REI: Research at Minority Serving Institutions
on Neurocognitive Mechanisms Underlying the Impact of Structural
Racism on the Substance Use Trajectory.
Date: February 3, 2025.
Time: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Shareen Amina Iqbal, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developing Digital Therapeutics for Substance Use
Disorders.
Date: February 5, 2025.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant applications.
Address: National Institute of Health National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Shareen Amina Iqbal, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 12, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-29831 Filed 12-17-24; 8:45 am]
BILLING CODE 4140-01-P
